Lipidor AB (publ)

Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.